DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for peripheral nervous system disease — screening already-approved drugs against its 27-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePeripheral nervous system disease maps to a 27-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for peripheral nervous system disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transthyretin (TTR) — TTR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2,4-dimethylphenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8C86 · 1.1 Å · ligand (2,4-dimethylphenyl)(4-hydroxy-3-methoxy-5-nitrophenyl)methanone (TQ0). Experimental structure, not a prediction.
What the evidence adds up to
A 2009 study of a mutant mouse line generated by ENU mutagenesis identified two interacting point mutations that together produce adult-onset transitory hindlimb paralysis and severe peripheral neuropathy. One mutation causes partial loss of function in the phosphatidate phosphatase gene Lpin1; the other truncates the neuronal cell adhesion molecule NrCAM. The Lpin1 single mutant and the double mutant show similar levels of demyelination and aberrant myelin structures, but the double mutant has more severe electrophysiological abnormalities. The Nrcam single mutant has normal sciatic nerve morphology and only a mild electrophysiological defect. The two defects do not add together; they act synergistically, and the authors propose that absence of NrCAM in a demyelinating environment impairs remyelination. No drug was tested in this study.
A 2020 review on drug repurposing in neurological diseases notes that the approach studies clinically approved drugs in one disease to see if they have therapeutic value in another, and that it overcomes financial and timeline shortages of traditional drug development. The review states that the structural complexity of the nervous system and blood–brain barrier permeability make new drug development in neuropathological conditions more difficult than in other organs, so repurposing is particularly important. It summarises repurposing candidates currently in clinical trials for neurological diseases, their potential mechanisms, and preliminary results, but does not name any specific drug or report any concrete outcome data for peripheral nervous system disease.
The remaining abstracts are general: a 2005 clinical guide to evaluating patients with peripheral nervous system complaints, a 1990 review of selective neuronal vulnerability in animal models and human diseases, a 1976 book review noting that guidance on selecting appropriate medication is sometimes lacking, and a 2016 editorial on screening methodologies for CNS disorders. None of these contain drug-specific results for peripheral nervous system disease.
What is still missing is any clinical trial of a repurposed drug specifically for peripheral neuropathy that reports response rates or survival in patients. The mouse study identifies a synergistic genetic mechanism but no pharmacological intervention. The repurposing review is a general framework with no concrete data for this disease. No funding for a repurposing trial in peripheral neuropathy is described, no patient stratification strategy is proposed, and no drug name appears in any of the abstracts that could be taken forward.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Neuroscience · 2009 · 24 citations · open access
Concurrent<i>Lpin1</i>and<i>Nrcam</i>Mouse Mutations Result in Severe Peripheral Neuropathy with Transitory Hindlimb Paralysis
AbstractPeripheral neuropathy is a broad category of disorders with a diverse etiology, grouped together by their common pathogenic effect on the peripheral nervous system (PNS). Because of the heterogeneity observed to be responsible for these disorders, a forward genetics method of gene discovery was used to identify additional affected pathways. In this report, we describe the mutant mouse line 20884, generated by N-ethyl-N-nitrosourea mutagenesis, which is characterized by adult-onset transitory hindlimb paralysis. Linkage mapping revealed that two point mutations are responsible for the phenotype: a partial loss-of-function mutation in the gene for phosphatidate phosphatase Lpin1 and a truncation mutation in the gene that encodes the neuronal cell adhesion molecule NrCAM. To investigate how the 20884 Lpin1 and Nrcam mutations interact to produce the paralysis phenotype, the double mutant and both single mutants were analyzed by quantitative behavioral, histological, and electrophysiological means. The Lpin1(20884) mutant and the double mutant are characterized by similar levels of demyelination and aberrant myelin structures. Nevertheless, the double mutant exhibits more severe electrophysiological abnormalities than the Lpin1(20884) mutant. The Nrcam(20884) mutant is characterized by normal sciatic nerve morphology and a mild electrophysiological defect. Comparison of the double mutant phenotype with the two single mutants does not point to an additive relationship between the two defects; rather, the Lpin1(20884) and Nrcam(20884) defects appear to act synergistically to produce the 20884 phenotype. It is proposed that the absence of NrCAM in a demyelinating environment has a deleterious effect, possibly by impairing the process of remyelination.
Journal of Osteopathic Medicine · 2005 · 12 citations · open access
Evaluating the Patient with Peripheral Nervous System Complaints
AbstractPatients commonly seek care from their family physicians for symptoms that are suggestive of peripheral nervous system (PNS) dysfunction. At some point in active practice, virtually all family physicians will be required to conduct at least an initial evaluation of a patient with PNS. The authors outline and describe common themes found in the symptoms and diagnoses of PNS dysfunctions. These themes may be useful to physicians when performing initial evaluations of patients with PNS dysfunctions. The authors also discuss diagnostic methods and effective therapeutic interventions for this population.
IntechOpen eBooks · 2020 · 6 citations · open access
Drug Repurposing in Neurological Diseases: Opportunities and Challenges
AbstractDrug repurposing or repositioning refers to “studying of clinically approved drugs in one disease to see if they have therapeutic value and do not trigger side effects in other diseases.” Nowadays, it is a vital drug discovery approach to explore new therapeutic benefits of existing drugs or drug candidates in various human diseases including neurological disorders. This approach overcomes the shortage faced during traditional drug development in grounds of financial support and timeline. It is especially hopeful in some refractory diseases including neurological diseases. The feature that structure complexity of the nervous system and influence of blood–brain barrier permeability often becomes more difficult to develop new drugs in neuropathological conditions than diseases in other organs; therefore, drug repurposing is particularly of utmost importance. In this chapter, we discuss the role of drug repurposing in neurological diseases and make a summarization of repurposing candidates currently in clinical trials for neurological diseases and potential mechanisms as well as preliminary results. Subsequently we also outline drug repurposing approaches and limitations and challenges in the future investigations.
Neuronal Disorders: Studies of Animal Models and Human Diseases
AbstractThe peripheral nervous system and the central nervous system (CNS) are comprised of assemblies of neurons that communicate via electrical and chemical signals. Different disease processes selectively affect specific populations of neurons and/or specific cell functions (i.e., "selective vulnerability" of neurons is a principal determinant of phenotypes of disease). New cellular and molecular biological approaches have begun to clarify some of the mechanisms of selective cell injury in human diseases and their animal models. Following a brief review of the normal biology of nerve cells, we use illustrations drawn from studies of experimental and human diseases to discuss the mechanisms of structural/chemical abnormalities that occur in a variety of neuronal disorders.
Journal of Neurology Neurosurgery & Psychiatry · 1976 · 1 citations · open access
LIMBIC AUTONOMIC NERVOUS SYSTEMS RESEARCH
AbstractIt is an aphorism in general medicine that 'there is no treatment in neurology'.If this were ever true, it is certainly not so today.This excellent book is, therefore, timely in providing a good source of reliable information on the applied pharmacology of neurological disease.A minor criticism of a book on therapeutics is that there is sometimes lack of guidance on the selection of the appropriate medication in different clinical situations.Perhaps this will be rectified in a further edition, which is sure to be called for.
JBS Special Issue: Innovative Screening Methodologies to Identify New Compounds for the Treatment of Central Nervous System Disorders
AbstractThere is a tremendous need for novel treatments of diseases of the central nervous system (CNS). It is widely appreciated that significant challenges are associated with first understanding the pathophysiology of chronic diseases and, second, designing new treatments. The slow progress of discovery and development can be devastating for patients, families, and caregivers as they await new treatment options. For chronic neurodegenerative disorders, drugs are not available that modify the course of these diseases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
